Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway

Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), is the only approved TKI that is effective against T315I mutations in patients with chronic myeloid leukemia (CML). Specific activation of Notch signaling in CML cells by ponatinib can be considered as the “on-target effect” on the tumor...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Med
Hlavní autoři: Madonna, Rosalinda, Pieragostino, Damiana, Cufaro, Maria Concetta, Doria, Vanessa, Del Boccio, Piero, Deidda, Martino, Pierdomenico, Sante Donato, Dessalvi, Christian Cadeddu, De Caterina, Raffaele, Mercuro, Giuseppe
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7141219/
https://ncbi.nlm.nih.gov/pubmed/32197359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9030820
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky